Thursday, 09 April 2020 9:07 pmSo, the cat is finally out of the bag at Circassia Pharmaceuticals: the company announced this morning that it would cancel the agreement with AstraZeneca for the US commercial rights to Tudorza and Duaklir in return for the FTSE 100 giant writing off a $150 million loan.
